$KAPA News

CEO.CA's Inside the Boardroom: Major U.S. Cancer Centers Are Testing This New Drug: Kairos Pharma

Kairos Pharma Targets Drug Resistance Mechanism Against Prostate Cancer

Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer

Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA

Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Kairos Pharma Announces 1-for-7 Reverse Stock Split

Kairos Pharma Announces 1-For-7 Reverse Stock Split, Effective Sept. 1

Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer

Kairos Pharma Partners With Bayer To Mull ENV-105 Inhibitor In Combination With Bayer’s XOFIGO

Kairos Pharma (KAPA) Stock Surges Over 22% After Hours: Why is it Moving?

CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever

Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market

All You Need to Know About Kairos Pharma, Ltd. (KAPA) Rating Upgrade to Buy

Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders

Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI

Kairos Pharma Q4 EPS $(0.07) Beats $(0.10) Estimate

Kairos Pharma signs deal for Celyn Therapeutics’ CL-273

Kairos Pharma Announces Signing of Binding Strategic Asset Acquisition of Exclusive Worldwide Rights to CL-273 From OrbiMed and Torrey Pines Investment-Backed Celyn Therapeutics

Kairos Pharma Enters Into Binding Terms To Acquire CL-273 From Celyn Therapeutics For Undisclosed Sum; Transaction Is Expected To Be Value‑Accretive

Kairos Pharma, Ltd. Announces Signing of Term Sheet for Strategic Asset Acquisition of Two Clinical Oncology Assets from Celyn Therapeutics